Table 2.
HLA class I, PD-L1 expression and clinicopathologic characteristics
| Clinicopathologic feature | HLA class I expression |
PD-L1 expression (1% cut-off) |
PD-L1 expression (50% cut-off) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Retained (normal) | Reduced (loss) | p-value | Negative (< 1%) | Positive (≥ 1%) | p-value | Negative (< 50%) | Positive (≥ 50%) | p-value | |
| Total | 34 (8.4) | 369 (91.6) | 338 (83.9) | 65 (16.1) | 380 (94.3) | 23 (5.7) | |||
| Age (yr) | |||||||||
| < 65 | 11 (5.5) | 190 (94.5) | .033 | 174 (86.6) | 27 (13.4) | .142 | 191 (95.0) | 10 (5.0) | .527 |
| ≥ 65 | 23 (11.4) | 179 (88.6) | 164 (81.2) | 38 (18.8) | 189 (93.6) | 13 (6.4) | |||
| Sex | |||||||||
| Male | 16 (8.4) | 175 (91.6) | .967 | 155 (81.2) | 36 (18.8) | .159 | 176 (92.1) | 15 (7.9) | .078 |
| Female | 18 (8.5) | 194 (91.5) | 183 (86.3) | 29 (13.7) | 204 (96.2) | 8 (3.8) | |||
| Smoking status | |||||||||
| Never | 19 (7.9) | 223 (92.1) | .604 | 206 (85.1) | 36 (14.9) | .402 | 231 (95.5) | 11 (4.5) | .218 |
| Ex or current | 15 (9.3) | 146 (90.7) | 132 (82.0) | 29 (18.0) | 149 (92.5) | 12 (7.5) | |||
| Differentiation | |||||||||
| WD | 2 (5.9) | 32 (94.1) | .422a | 34 (100.0) | 0 | < .001 | 34 (100) | 0 | .008a |
| MD | 25 (7.9) | 290 (92.1) | 270 (85.7) | 45 (14.3) | 300 (95.2) | 15 (4.8) | |||
| PD | 7 (13.0) | 47 (87.0) | 34 (63.0) | 20 (37.0) | 46 (85.2) | 8 (14.8) | |||
| Genetic statusb | |||||||||
| EGFR mutant | 17 (8.9) | 175 (91.1) | .860a | 175 (91.1) | 17 (8.9) | .003 | 190 (99.0) | 2 (1.0) | < .001a |
| ALK mutant | 1 (5.0) | 19 (95.0) | 17 (85.0) | 3 (15.0) | 18 (90.0) | 2 (10.0) | |||
| KRAS mutant | 2 (12.5) | 14 (87.5) | 10 (62.5) | 6 (37.5) | 12 (75.0) | 4 (25.0) | |||
| EGFR(–)/ALK(–)/KRAS(–) | 5 (10.0) | 45 (90.0) | 39 (78.0) | 11 (22.0) | 45 (90.0) | 5 (10.0) | |||
| Pleural invasion | |||||||||
| Negative | 19 (8.1) | 216 (91.9) | .764 | 199 (84.7) | 36 (15.3) | .601 | 224 (95.3) | 11 (4.7) | .294 |
| Positive | 15 (8.9) | 153 (91.1) | 139 (82.7) | 29 (17.3) | 156 (92.9) | 12 (7.1) | |||
| Vascular invasion | |||||||||
| Negative | 19 (6.3) | 283 (93.7) | .007 | 263 (87.1) | 39 (12.9) | .002 | 289 (95.7) | 13 (4.3) | .036 |
| Positive | 15 (14.9) | 86 (85.1) | 75 (74.3) | 26 (25.7) | 91 (90.1) | 10 (9.9) | |||
| Lymphatic invasion | |||||||||
| Negative | 19 (8.9) | 194 (91.1) | .712 | 184 (86.4) | 29 (13.6) | .146 | 206 (96.7) | 7 (3.3) | .027 |
| Positive | 15 (7.9) | 175 (92.1) | 154 (81.1) | 36 (18.9) | 174 (91.6) | 16 (8.4) | |||
| Perineural invasion | |||||||||
| Negative | 30 (7.9) | 350 (92.1) | .118a | 321 (84.5) | 59 (15.5) | .236a | 360 (94.7) | 20 (5.3) | .136a |
| Positive | 4 (17.4) | 19 (82.6) | 17 (73.9) | 6 (26.1) | 20 (87.0) | 3 (13.0) | |||
| Tumor size (cm) | |||||||||
| ≤ 3 | 13 (5.4) | 229 (94.6) | .007 | 208 (86.0) | 34 (14.0) | .164 | 233 (96.3) | 9 (3.7) | .035 |
| > 3 | 21 (13.0) | 140 (87.0) | 130 (80.7) | 31 (19.3) | 147 (91.3) | 14 (8.7) | |||
| N stage | |||||||||
| N0 | 19 (6.9) | 256 (93.1) | .106 | 238 (86.5) | 37 (13.5) | .032 | 261 (94.9) | 14 (5.1) | .434 |
| ≥ N1 | 15 (11.7) | 113 (88.3) | 100 (78.1) | 28 (21.9) | 119 (93.0) | 9 (7.0) | |||
| Stage | |||||||||
| I | 14 (6.0) | 220 (94.0) | .012 | 204 (87.2) | 30 (12.8) | .079 | 222 (94.9) | 12 (5.1) | .484a |
| II | 6 (7.2) | 77 (92.8) | 64 (77.1) | 19 (22.9) | 76 (91.6) | 7 (8.4) | |||
| III | 14 (16.3) | 72 (83.7) | 70 (81.4) | 16 (18.6) | 82 (95.3) | 4 (4.7) | |||
| Stage I and others | |||||||||
| I | 14 (6.0) | 220 (94.0) | .037 | 204 (87.2) | 30 (12.8) | .034 | 222 (94.9) | 12 (5.1) | .555 |
| ≥ IIa | 20 (11.8) | 149 (88.2) | 134 (79.3) | 35 (20.7) | 158 (93.5) | 11 (6.5) | |||
| PD-L1 status (1% cutoff) | |||||||||
| Negative | 24 (7.1) | 314 (92.9) | .028 | ||||||
| Positive | 10 (15.4) | 55 (84.6) | |||||||
a
p-value was obtained by Fisher exact test;
b
Genetic status was evaluable for 278 patients.